• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Revista Cubana de Hematología, Inmunología y Hemoterapia >Trasplante de progenitores hematopoy??ticos aut?3logo en gammapat?-as monoclonales: primeros resultados del Hospital “Hermanos Ameijeiras”
【24h】

Trasplante de progenitores hematopoy??ticos aut?3logo en gammapat?-as monoclonales: primeros resultados del Hospital “Hermanos Ameijeiras”

机译：移植血红素莫里康祖的祖联祖？？？-Gamapat？-to单克隆：医院“兄弟A​​meijeiras”的第一个结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The recent advances in the management of multiple myeloma (MM) during the last years have included the autologous hematopoietic stem cell transplantation (auto-HSCT) to the treatment strategy of these patients. Objective: To present the first results in the "Hermanos Ameijeiras" hospital (HAH) with the application of auto-HSCT in patients with monoclonal gammopathies (MG) using high doses of melphalan (HD-Mel) as conditioning regimen (CR) and its impacton overall survival (OS). Methods: A retrospective study of all patients with MG who underwent auto-HSCT in the Hematology Service of the HAH in the period between 2009 and 2018 wasmade. The final sample comprised 14 cases. Results: The average age was 53.5 years; the majority had diagnosis of MM (85.7%) and all of them were diagnosed in stage III of Durie-Salmon; as CR 64.2% received HD-mel, at 200 mg/m2. The recovery of neutrophil and platelet counts occurred on average at 11.4 and 12 days respectively. Transplant related mortality (TRM) at day +30 was 7.1%. The probability of OS at 2 years was higher than 90% and at 5 years of 68%. Conclusions: It was verified that the performance of auto-HSCT with the use of HD-Mel as CR in patients with MG is a feasible procedure in our country with a relatively low TRM. It was possible to demonstrate that the inclusion of auto-HSCT in the treatment considerably improves the survival expectations of these patients.
机译：介绍：在过去几年中，多发性骨髓瘤（mm）的近期进程包括自体造血干细胞移植（Auto-Hsct），以对这些患者的治疗策略。目的：展示“Hermanos Ameijeiras”医院（HAH）的第一个结果，在使用高剂量的莫酚（HD-MEL）作为调理方案（CR）及其患者的单克隆血曲调（MG）患者的患者电影局整体生存（OS）。方法：2009年至2018年期间，在HAH的血液学服务中接受了自动HSCT的所有患者的回顾性研究。最终样品组成14例。结果：平均年龄为53.5岁;大多数人诊断为mm（85.7％），所有这些都被诊断为Durie-salmon的III阶段;作为Cr 64.2％的HD-MEL，200mg / m 2。中性粒细胞和血小板计数的回收率平均分别在11.4和12天内发生。日期+30日移植相关死亡率（TRM）为7.1％。 2年OS的概率高于90％，5年为68％。结论：验证了在MG患者中使用HD-MEL的Auto-HSCT的性能是我国的可行程序，具有相对较低的TRM。有可能证明包含自动HSCT在治疗中的含量显着提高了这些患者的存活期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号